
Synlab remains in talks with Cinven five months after initial approach
Takeover talks remain ongoing between Synlab and Cinven almost five months after the financial sponsor’s original expression of interest, according to two sources familiar with the situation.
Cinven, which already owns 43% of the target’s shares, made its initial EUR 10 per share indicative offer for the laboratory diagnostics provider in March.
Shares in Synlab traded as high as EUR 9.88 during May, shortly before Synlab confirmed it was working with Lazard to advise on Cinven’s approach.
An absence of news on the situation since then has seen the stock drift lower to close last week (5 August) at EUR 8.92 and a 12% spread to Cinven’s indicative bid.
Synlab is scheduled to present 1H23 results on Wednesday (9 August) and an update on the status of talks could be provided then, one of the sources said. Synlab would be expected to make an announcement if the talks had ended, the same source added.
A reason for the lack of news on the deal could be that Cinven was waiting for more visibility on the regulatory situation in France, which has recently been resolved, a Synlab minority shareholder said.
France's National Health Insurance system at the end of July set a new growth ceiling for remuneration of laboratories over the next three years. This gives more visibility on reimbursement in France for Synlab and was significantly better than expected, according to a Deutsche Bank analyst note. The analysts upgraded their target share price on Synlab from EUR 9 to EUR 12 following the regulatory update. France is one of Synlab’s most important markets, accounting for 21% of revenue during 2022, as reported.
Difficult financing markets could also be a reason behind the talks slow progress, the shareholder said.
Cinven’s EUR 10 per share expression of interest was considered below fair value by shareholders polled by Mergermarket during March. Cinven listed Synlab in April 2021 at EUR 18 per share and remains its largest shareholder. Synlab is headquartered in Munich and has a EUR 2bn market cap.
Synlab and Cinven declined to comment.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater